touchREVIEWS in RMD. 2022;1(2):40–1 DOI: https://doi.org/10.17925/RMD.2022.1.2.40
Systemic lupus erythematosus (SLE) is a chronic, relapsing and remitting autoimmune disease,1 affecting 13–7,714 per 100,000 individuals.2 Inflammation in SLE can lead to tissue damage in any organ system, frequently due to acute flares,1 with commonly affected organ systems including the cardiopulmonary, central nervous system, haematological, mucocutaneous, musculoskeletal and renal systems.3 Consequently, patients with SLE can display a diverse […]